NASDAQ:KALA - Kala Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.78 -0.26 (-4.30 %) (As of 01/17/2019 04:00 PM ET)Previous Close$6.04Today's Range$5.55 - $6.0752-Week Range$4.03 - $18.30Volume363,162 shsAverage Volume188,205 shsMarket Capitalization$210.88 millionP/E Ratio-0.99Dividend YieldN/ABeta1 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts. Receive KALA News and Ratings via Email Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALA Previous Symbol CUSIPN/A Webwww.kalarx.com Phone781-996-5252Debt Debt-to-Equity Ratio0.30 Current Ratio6.34 Quick Ratio6.27Price-To-Earnings Trailing P/E Ratio-0.99 Forward P/E Ratio-2.63 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.58Profitability EPS (Most Recent Fiscal Year)($5.84) Net Income$-42,210,000.00 Net MarginsN/A Return on Equity-72.11% Return on Assets-52.71%Miscellaneous Employees37 Outstanding Shares33,800,000Market Cap$210.88 million OptionableOptionable Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions What is Kala Pharmaceuticals' stock symbol? Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA." How were Kala Pharmaceuticals' earnings last quarter? Kala Pharmaceuticals Inc (NASDAQ:KALA) released its quarterly earnings data on Thursday, November, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.01. View Kala Pharmaceuticals' Earnings History. When is Kala Pharmaceuticals' next earnings date? Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for Kala Pharmaceuticals. What price target have analysts set for KALA? 4 Wall Street analysts have issued 12 month price targets for Kala Pharmaceuticals' stock. Their predictions range from $15.00 to $51.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $25.75 in the next year. This suggests a possible upside of 345.5% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals. What is the consensus analysts' recommendation for Kala Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals. What are Wall Street analysts saying about Kala Pharmaceuticals stock? Here are some recent quotes from research analysts about Kala Pharmaceuticals stock: 1. According to Zacks Investment Research, "Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States. " (1/2/2019) 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $495M, which includes a discounted cash flow-based asset value of $570M for INVELTYS (100% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate, excluding $75M debt." (12/27/2018) Has Kala Pharmaceuticals been receiving favorable news coverage? Media stories about KALA stock have trended very positive on Thursday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 3.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. Who are some of Kala Pharmaceuticals' key competitors? Some companies that are related to Kala Pharmaceuticals include Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Alder Biopharmaceuticals (ALDR), Epizyme (EPZM), AC Immune (ACIU), Y-mAbs Therapeutics (YMAB), Athenex (ATNX), CytomX Therapeutics (CTMX), Dynavax Technologies (DVAX), Revance Therapeutics (RVNC), Radius Health (RDUS), Principia Biopharma (PRNB) and G1 Therapeutics (GTHX). Who are Kala Pharmaceuticals' key executives? Kala Pharmaceuticals' management team includes the folowing people: Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 52)Mr. Todd Bazemore, Chief Operating Officer (Age 48)Dr. Kim Brazzell, Chief Medical Officer (Age 65)Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory BoardMs. Mary Reumuth CPA, CFO & Treasurer (Age 43) When did Kala Pharmaceuticals IPO? (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of Kala Pharmaceuticals? Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kala Pharmaceuticals' stock price today? One share of KALA stock can currently be purchased for approximately $5.78. How big of a company is Kala Pharmaceuticals? Kala Pharmaceuticals has a market capitalization of $210.88 million. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe. What is Kala Pharmaceuticals' official website? The official website for Kala Pharmaceuticals is http://www.kalarx.com. How can I contact Kala Pharmaceuticals? Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected] MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 157 (Vote Outperform)Underperform Votes: 155 (Vote Underperform)Total Votes: 312MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: Is a Roth IRA right for you?